<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxcarbazepine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxcarbazepine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxcarbazepine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10935" href="/d/html/10935.html" rel="external">see "Oxcarbazepine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12664" href="/d/html/12664.html" rel="external">see "Oxcarbazepine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F204790"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Oxtellar XR;</li>
<li>Trileptal</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867792"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-OXcarbazepine;</li>
<li>JAMP-OXcarbazepine [DSC];</li>
<li>Trileptal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F204825"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Miscellaneous</li></ul></div>
<div class="block doa drugH1Div" id="F204795"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Before use, test for the HLA-B*1502 allele in patients at increased genetic risk (eg, those of Asian ancestry, including South Asian patients) for oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis. Do not initiate oxcarbazepine in patients who test positive for HLA-B*1502 when other options are available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29392710','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29392710','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31008289-31f3-4083-91b3-0190ad6d466a">Focal onset seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal (partial) onset seizures: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Monotherapy and adjunctive therapy in the treatment of patients with focal onset seizures with or without secondary generalized tonic-clonic seizures<b>.</b> Avoid use in myoclonic or generalized nonmotor (absence) seizures due to potential to worsen generalized convulsions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NICE.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NICE.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 300 to 600 mg/day in 2 divided doses. May increase dose by ≤600 mg/day increments at weekly intervals to a maximum dose of 2.4 g/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10881247','lexi-content-ref-16962380','lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10881247','lexi-content-ref-16962380','lexi-content-ref-Schachter.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Initial: 600 mg once daily. May increase dose by 600 mg/day increments at weekly intervals to a maximum dose of 2.4 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24359313','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24359313','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f4eb55b3-bb48-4348-b998-a96e37156dae">Trigeminal neuralgia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trigeminal neuralgia (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 300 to 600 mg/day in 2 divided doses; adjust dose based on response and tolerability in increments of 300 mg/day every ≥3 days up to a maximum dose of 1.8 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18378142','lexi-content-ref-Ho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18378142','lexi-content-ref-Ho.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>In chronic therapy, withdraw gradually over 1 to 6 months based upon individual circumstance to minimize the potential of increased seizure frequency (in patients with epilepsy) unless safety concerns require more rapid withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18505998','lexi-content-ref-19949566','lexi-content-ref-Schachter.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18505998','lexi-content-ref-19949566','lexi-content-ref-Schachter.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991782"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (CrCl &lt;30 mL/minute): Immediate release, Extended release: Therapy should be initiated at one-half the usual starting dose (300 mg daily) and increased slowly to achieve desired clinical response (eg, 300 to 450 mg daily at weekly intervals).</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD (on dialysis): Immediate release formulations should be used instead of extended release formulation.</p></div>
<div class="block doha drugH1Div" id="F50988945"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: There are no dosage adjustments provided in the manufacturer's labeling; use caution (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: There are no dosage adjustments provided in the manufacturer's labeling; use is not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F204796"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Immediate release: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b>Extended release: Initial: 300 mg or 450 mg once daily; dosage may be increased by 300 to 450 mg/day increments at weekly intervals to desired clinical response.</p></div>
<div class="block dop drugH1Div" id="F204810"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12664" href="/d/html/12664.html" rel="external">see "Oxcarbazepine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Immediate-release preparations (oral suspension and tablets) are interchangeable on a mg per mg basis; immediate-release and extended-release preparations are <b>not</b> bioequivalent and not interchangeable on a mg per mg basis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13d71256-9e7f-437a-846a-04de11857882">Partial-onset seizures, monotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Partial-onset seizures, monotherapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;4 years: Limited data available: Oral: Immediate release (Trileptal): Initial: 7.5 to 10 mg/kg/day in 2 divided doses; titrate dose in increments of 7.5 to 10 mg/kg/day every 5 to 7 days as tolerated; maximum daily dose: 60 mg/kg/<b>day</b>. If intolerance develops during titration, decrease dose by 5 mg/kg/day as needed. Dosing based on an open-label study and 2 retrospective chart reviews (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16939855','lexi-content-ref-16243221','lexi-content-ref-24081427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16939855','lexi-content-ref-16243221','lexi-content-ref-24081427'])">Ref</a></span>). The open-label study enrolled patients 1 month to &lt;4 years weighing ≥3 kg; 24 patients were enrolled, of which 10 received oxcarbazepine as monotherapy; oxcarbazepine was well tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initiation of monotherapy:</i> Patients not receiving concomitant antiseizure drugs: Immediate release (Trileptal):</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Oral: 8 to 10 mg/kg/day in 2 divided doses; usual initial daily dose in adults is 600 mg/day; increase dose every third day by 5 mg/kg/day to achieve the recommended monotherapy maintenance dose by weight, as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:10em;">20 to &lt;25 kg: Oral: 600 to 900 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">25 to &lt;35 kg: Oral: 900 to 1,200 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">35 to &lt;45 kg: Oral: 900 to 1,500 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">45 to &lt;50 kg: Oral: 1,200 to 1,500 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">50 to &lt;60 kg: Oral: 1,200 to 1,800 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">60 to &lt;70 kg: Oral: 1,200 to 2,100 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">≥70 kg: Oral: 1,500 to 2,100 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to monotherapy:</i> Patients receiving concomitant antiseizure drugs: Oral: Initial: 8 to 10 mg/kg/day in 2 divided doses (usual initial daily dose in adults is 600 mg/day), with a simultaneous initial reduction of the dose of concomitant antiseizure drugs; withdraw concomitant antiseizure drugs completely over 3 to 6 weeks, while increasing oxcarbazepine dose as needed by no more than 10 mg/kg/day at approximately weekly intervals; increase oxcarbazepine dose to achieve the recommended monotherapy maintenance dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Immediate release (Trileptal):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initiation of monotherapy:</i> Patients not receiving prior antiseizure drugs: Oral: Initial: 300 mg twice daily. Increase dose by 300 mg/day every third day to a maintenance dose of 1,200 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Conversion to monotherapy:</i> Patients receiving concomitant antiseizure drugs: Oral: Initial: 300 mg twice daily while simultaneously reducing the dose of concomitant antiseizure drugs. Withdraw concomitant antiseizure drugs completely over 3 to 6 weeks, while increasing the oxcarbazepine dose in increments of 600 mg/day at weekly intervals up to target maintenance dose of 2,400 mg/day in 2 divided doses in about 2 to 4 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e90cc2ac-3a55-487d-a871-e503703fbaa0">Partial-onset seizures, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Partial-onset seizures, adjunctive therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release (Trileptal):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;2 years: Limited data available: Oral: Initial: 7.5 to 10 mg/kg/day in 2 divided doses; titrate dose in increments of 7.5 to 10 mg/kg/day every 5 to 7 days; maximum daily dose: 60 mg/kg/<b>day</b>. If intolerance develops during titration, decrease dose by 5 mg/kg/day as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16939855','lexi-content-ref-16243221','lexi-content-ref-16275822','lexi-content-ref-24081427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16939855','lexi-content-ref-16243221','lexi-content-ref-16275822','lexi-content-ref-24081427'])">Ref</a></span>). Dosing based on a multicenter randomized trial, an open-label study, and 2 retrospective chart reviews; both prospective studies enrolled patients 1 month to &lt;4 years weighing ≥3 kg. The multicenter study randomized 128 patients to either high-dose (60 mg/kg/day) or low-dose (10 mg/kg/day) regimens; patients receiving the high-dose regimen had a significantly greater decrease in seizure frequency per 24 hours compared to the low dose group. Oxcarbazepine was generally well tolerated; however, the high dose group experienced more adverse effects although they were generally mild in severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16275822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16275822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;4 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;20 kg: Oral: Initial: 8 to 10 mg/kg/day in 2 divided doses; may consider initiating at a higher dose of 16 to 20 mg/kg/day due to increased clearance in this age; increase dose slowly over 2 to 4 weeks; maximum daily dose: 60 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥20 kg: Oral: Initial: 8 to 10 mg/kg/day in 2 divided doses (usual maximum initial daily dose: 600 mg<b>/day</b>); increase dose slowly over 2 to 4 weeks; maximum daily dose: 60 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> In children 2 to 4 years of age, 50% of patients were titrated to a final dose of at least 55 mg/kg/day with target dose of 60 mg/kg/day. Due to a higher drug clearance, children 2 to &lt;4 years of age may require up to twice the dose per body weight compared to adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Oral: 8 to 10 mg/kg/day in 2 divided doses; usual maximum initial daily dose: 600 mg/<b>day</b>; increase dose slowly over 2 weeks to the target maintenance dose by weight, as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:10em;">20 to 29 kg: Oral: 900 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">29.1 to 39 kg: Oral: 1,200 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;39 kg: Oral: 1,800 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Use of these pediatric target maintenance doses in one clinical trial resulted in doses ranging from 6 to 51 mg/kg/day (median dose: 31 mg/kg/day) in pediatric patients 4 to 16 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10881246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10881246'])">Ref</a></span>). Due to a higher drug clearance, children 4 to ≤12 years of age may require a 50% higher dose per body weight compared to adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: Oral: Initial: 300 mg twice daily; dose may be increased by ≤600 mg/day increments at weekly intervals up to target maintenance dose of 1,200 mg/day in 2 divided doses. Although doses &gt;1,200 mg/day were somewhat more efficacious, most patients were unable to tolerate 2,400 mg/day (due to CNS effects).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release (Oxtellar XR):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 6 to ≤16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: Oral: 8 to 10 mg/kg/day once daily; maximum initial daily dose: 600 mg/<b>day</b> during the first week of therapy. Increase dose at weekly intervals in 8 to 10 mg/kg/day increments over 2 to 3 weeks (maximum dosage incremental increase: 600 mg/dose) to the target maintenance dose based on weight, as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose:</p>
<p style="text-indent:-2em;margin-left:10em;">20 to 29 kg: Oral: 900 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">29.1 to 39 kg: Oral: 1,200 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;39 kg: Oral: 1,800 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: Oral: Initial: 600 mg once daily; dosage may be increased by 600 mg/day increments at weekly intervals. Recommended daily dose is 1,200 to 2,400 mg once daily. Although daily doses &gt;1,200 mg daily were somewhat more efficacious, most patients were unable to tolerate 2,400 mg/day (due to CNS effects).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion from immediate release (Trileptal) to extended release (Oxtellar XR):</b> Children ≥6 years and Adolescents: Higher doses of Oxtellar XR may be necessary; on a mg per mg basis dosage forms are not bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151094"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (CrCl &lt;30 mL/minute):</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release (eg, Trileptal): Children ≥2 years and Adolescents: Oral: Therapy should be initiated at lower starting dose (eg, one-half the usual starting dose) and increased slowly to achieve desired clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (eg, Oxtellar XR):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to ≤16 years: Oral: There are no specific recommendations for this age group in the manufacturer's labeling; in older pediatric patients, initial dosage reductions and a slower titration are recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: Oral: Therapy should be initiated at one-half the usual starting dose (300 mg/day) and increased slowly at weekly intervals in 300 to 450 mg/day increments to achieve desired clinical response.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage kidney disease (ESKD) (on dialysis): Immediate-release formulations should be used instead of extended-release formulation.</p></div>
<div class="block dohp drugH1Div" id="F51151095"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: Immediate release (eg, Trileptal), Extended release (eg, Oxtellar XR): No dosage adjustments are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release (eg, Trileptal): There are no dosage adjustments in the manufacturer's labeling; has not been studied; use caution particularly if concomitant antiseizure therapy</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (eg, Oxtellar XR): There are no dosage adjustment in the manufacturer's labeling; use is not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56332405"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Blood dyscrasias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agranulocytosis</b>,<b> leukopenia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724','lexi-content-ref-19196947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724','lexi-content-ref-19196947'])">Ref</a></span>), <b>aplastic anemia</b>, <b>pancytopenia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17414253','lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17414253','lexi-content-ref-30999724'])">Ref</a></span>), and <b>thrombocytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17690747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17690747'])">Ref</a></span>) have been reported with oxcarbazepine. One retrospective study in pediatric patients in Korea reported an oxcarbazepine-induced leukopenia rate of ~5% which led to pancytopenia in two patients (1%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724'])">Ref</a></span>). Leukopenia often reverses, even with continued treatment; however, some cases may require dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724'])">Ref</a></span>). The prevalence of thrombocytopenia is reported to be ~2% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17690747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17690747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; may be due to immune-mediated or toxic mechanisms, similar to carbamazepine due to structural similarity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724'])">Ref</a></span>). Thrombocytopenia may be due to hyper-destruction of platelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17690747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17690747'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; days or months after initiation of therapy. In one study, onset of leukopenia was observed 11 days to 14 years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Leukopenia: Possible male predominance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30999724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30999724'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Thrombocytopenia: Correlation with daily dose but not serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17690747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17690747'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of delayed hypersensitivity reactions, ranging from mild with <b>maculopapular eruption</b> (also known as morbilliform rash) to severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome</b>,<b> toxic epidermal necrolysis </b>(SJS/TEN), and<b> drug reaction with eosinophilia and systemic symptoms </b>(DRESS) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33188522','lexi-content-ref-18821094','lexi-content-ref-26288485','lexi-content-ref-30605267','lexi-content-ref-29610167','lexi-content-ref-31997613','lexi-content-ref-31840232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33188522','lexi-content-ref-18821094','lexi-content-ref-26288485','lexi-content-ref-30605267','lexi-content-ref-29610167','lexi-content-ref-31997613','lexi-content-ref-31840232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Delayed hypersensitivity reactions, including maculopapular eruptions and SCARs are T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-26339470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-26339470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed hypersensitivity reactions: Varied. Maculopapular rash usually occurs within 2 to 4 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23744424','lexi-content-ref-27730770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23744424','lexi-content-ref-27730770'])">Ref</a></span>). SCARs usually occur 1 to 8 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.2014'])">Ref</a></span>); reexposure may lead to more rapid onset (usually with 1 to 4 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-27086495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-27086495'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• HLA-B*1502 allele increases risk of SJS/TEN especially in South-East Asian populations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27913699','lexi-content-ref-29392710','lexi-content-ref-29370880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27913699','lexi-content-ref-29392710','lexi-content-ref-29370880'])">Ref</a></span>); avoidance of oxcarbazepine should be considered in oxcarbazepine-naive patients who test positive for HLA-B*1502 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29392710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29392710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Viral reactivation, in particular human herpesvirus 6 (HHV-6) reactivation may be associated with a prolonged and more severe course of DRESS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28256714','lexi-content-ref-25369238','lexi-content-ref-31840232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28256714','lexi-content-ref-25369238','lexi-content-ref-31840232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• High degree of cross-reactivity exists between aromatic antiseizure medications, including phenytoin, carbamazepine, phenobarbital, primidone, and oxcarbazepine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18490142','lexi-content-ref-25933949','lexi-content-ref-18981374','lexi-content-ref-27730770']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18490142','lexi-content-ref-25933949','lexi-content-ref-18981374','lexi-content-ref-27730770'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyponatremia</b> is a common adverse reaction with oxcarbazepine in adult and pediatric patients. The reported incidence of oxcarbazepine-induced hyponatremia varies greatly in the literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738','lexi-content-ref-16380624','lexi-content-ref-12571784','lexi-content-ref-24378204','lexi-content-ref-8112243','lexi-content-ref-11460891']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738','lexi-content-ref-16380624','lexi-content-ref-12571784','lexi-content-ref-24378204','lexi-content-ref-8112243','lexi-content-ref-11460891'])">Ref</a></span>). In a cohort study of adult patients with epilepsy treated with either carbamazepine or oxcarbazepine, hyponatremia (serum sodium ≤134 mmol/L) occurred in 46% of patients receiving oxcarbazepine; 22% of those cases classified as severe hyponatremia (≤128 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738'])">Ref</a></span>). An earlier study demonstrated an incidence of 30% and 12% for hyponatremia and severe hyponatremia, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16380624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16380624'])">Ref</a></span>). In a study of pediatric patients, hyponatremia without clinical symptoms occurred in 27% of patients receiving oxcarbazepine; 3% of cases were severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12571784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12571784'])">Ref</a></span>). Hyponatremia associated with oxcarbazepine in the clinical trials was mostly asymptomatic. Study patients were monitored frequently with interventions such as reduction in fluid intake, dose reductions, or discontinuation of oxcarbazepine. Cases of symptomatic hyponatremia have been reported mostly with mild symptoms (eg, dizziness, diplopia, confusion, lethargy, headache), but symptoms can lead to seizures and in very severe cases coma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; unknown but may be caused by direct activation or enhanced sensitivity of vasopressin V<sub>2 </sub>receptors (V<sub>2</sub>R), which play a key role in water reabsorption, as well as a direct effect on the renal collecting tubules. Hyponatremia does not appear to result from increased release of antidiuretic hormone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12112108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12112108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; clinically significant hyponatremia generally occurs during the first 3 months of treatment; although, there are reports of patients who developed a serum sodium &lt;125 mmol/L more than 1 year after initiation of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses/serum drug concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738','lexi-content-ref-20881597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738','lexi-content-ref-20881597'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;40 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other antiseizure medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28542738','lexi-content-ref-20881597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28542738','lexi-content-ref-20881597'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications known to decrease serum sodium (eg, diuretics)</p>
<p style="text-indent:-2em;margin-left:6em;">• The study in pediatric patients did not find dose, serum levels, age, or concurrent use of other antiseizure medications to be predictive for the development of hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12571784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12571784'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Oxcarbazepine is associated with CNS effects in adult and pediatric patients, including cognitive symptoms (eg, psychomotor slowing, <b>lack of concentration</b>, <b>speech disturbance </b>or language problems), <b>dizziness</b>, <b>drowsiness</b>,<b> fatigue</b>, and coordination abnormalities (eg,<b> ataxia</b> and <b>abnormal gait</b>). A postmarketing surveillance study obtained from dispensed British National Health Service prescriptions reported that the most frequent clinical reason for discontinuation was drowsiness/sedation (~2.5% of cohort) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20132298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20132298'])">Ref</a></span>). According to the manufacturer, psychiatric effects such as manic behavior and psychosis have been reported. However, oxcarbazepine has also been associated with positive mood-stabilizing properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11444724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11444724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: May be dose-related; related to pharmacologic action.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• May be dose related</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent administration of other CNS sedating agents</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal ideation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antiseizure medications have been associated with <b>suicidal ideation</b> and <b>suicidal tendencies</b>. However, the FDA meta-analysis has been criticized due to several important limitations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21157540','lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21157540','lexi-content-ref-22994856'])">Ref</a></span>). The risk of suicide is increased in epilepsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19453718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19453718'])">Ref</a></span>), but the occurrence of suicidal ideation/tendencies in epilepsy is multifactorial. While some antiseizure medications (but not all) have been associated with treatment-emergent psychiatric effects such as anxiety and depression, other factors such as post-ictal suicidal behavior and pertinent patient history must also be evaluated to provide an accurate assessment of risk for any individual drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22994856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22994856'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; peak incidence of suicidality across antiseizure medications (not specific to individual agents) has been noted to occur between 1 and 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254','lexi-content-ref-20388896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254','lexi-content-ref-20388896'])">Ref</a></span>). A review of clinical trials noted that risk extended from 1 week to 24 weeks of therapy, corresponding to the duration of most trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889','lexi-content-ref-18698874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889','lexi-content-ref-18698874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use in conditions other than epilepsy or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In patients with bipolar disorder, risk for repeat suicide attempt was increased in patients with alcohol/substance abuse disorder, rapid cycling, and earlier age at onset of first manic episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28190254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28190254'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F204754"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence of adverse effects is from monotherapy and adjunctive antiseizure drug studies. Incidence in children was similar. Incidence is reported for immediate release (IR) formulation unless otherwise noted as extended release (ER).</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (ER, IR: 1% to 46%) (Berghuis 2017, Dong 2005, Holtman 2002)<span class="lexi-table-link-container"> (<a aria-label="Hyponatremia table link" class="lexi-table-link" data-table-id="lexi-content-hyponatremia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyponatremia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyponatremia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyponatremia" frame="border" id="lexi-content-hyponatremia" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Hyponatremia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Carbamazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Carbamazepine [C] or Placebo [P])</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">C: 1,132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤134 mEq/L; Berghuis 2017</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">C: 451</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤134 mEq/L; Dong 2005</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤135 mEq/L; Holtman 2002</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">289</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">C: 1,132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤128 mEq/L; Berghuis 2017</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">97</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">C: 451</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤128 mEq/L; Dong 2005</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Shift in serum sodium concentrations from normal to low (&lt;135 mEq/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Shift in serum sodium concentrations from normal to low (&lt;135 mEq/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,524</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium of less than 125 mmol/L at some point during treatment</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">P: 166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">75</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Sodium level ≤125 mEq/L; Holtman 2002</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">P: 166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Clinically significant hyponatremia</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5% to 13%), nausea (15% to 25%), vomiting (ER: 15%; IR: 7% to 33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (ER: 1% to 3%; IR: 2% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Ataxia table link" class="lexi-table-link" data-table-id="lexi-content-ataxia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ataxia')">table 2</a>)</span><span class="table-link" style="display:none;">Ataxia</span>, dizziness (ER, IR: 20% to 41%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 3</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (ER: 12% to 14%; IR: 19% to 31%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 4</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, fatigue (ER: 3% to 6%; IR: 12% to 21%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 5</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, headache (ER: 8% to 15%; IR 13% to 32%), vertigo (2% to 12%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ataxia" frame="border" id="lexi-content-ataxia" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Ataxia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients not previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients not previously treated with other antiseizure medications; defined as "abnormal coordination"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy; defined as "abnormal coordination"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications; defined as "abnormal coordination"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy; defined as "abnormal coordination"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">123</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">123</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients not previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">123</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">123</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia (ER: 10% to 13%; IR: 12% to 30%), nystagmus disorder (ER: 3%; IR: 2% to 20%), visual disturbance (ER: 1% to 3%; IR: 4% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2%), edema (2%), hypotension (1%), lower extremity edema (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (1% to 2%), diaphoresis (3%), skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (2%), increased thirst (2%), weight gain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (5%), constipation (4% to 5%), diarrhea (7%), dysgeusia (5%), dyspepsia (ER, IR: 2% to 6%), gastritis (ER, IR: 2% to 3%), toothache (2%), upper abdominal pain (ER: 3%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (2%), urinary tract infection (5%), vaginitis (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (4%), lymphadenopathy (2%), purpuric rash (2%), rectal hemorrhage (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (2%), viral infection (7%),</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (ER: ≤3%; IR: 5% to 10%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Gait table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-gait" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-gait')">table 6</a>)</span><span class="table-link" style="display:none;">Abnormal Gait</span>, abnormality in thinking (2%), amnesia (4% to 5%), anxiety (7%), balance impairment (ER: 7%), confusion (7%), dysmetria (1% to 2%), emotional lability (3% to 8%), falling (4%), feeling abnormal (1%), hypoesthesia (3%), insomnia (2% to 6%), lack of concentration (2%)<span class="lexi-table-link-container"> (<a aria-label="Lack of Concentration table link" class="lexi-table-link" data-table-id="lexi-content-lack-of-concentration" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-lack-of-concentration')">table 7</a>)</span><span class="table-link" style="display:none;">Lack of Concentration</span>, myasthenia (1% to 2%), nervousness (2% to 7%), seizure (2%; decreased seizure threshold [exacerbation of seizures]: 5%), speech disturbance (1% to 3%)<span class="lexi-table-link-container"> (<a aria-label="Speech Disturbance table link" class="lexi-table-link" data-table-id="lexi-content-speech-disturbance" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-speech-disturbance')">table 8</a>)</span><span class="table-link" style="display:none;">Speech Disturbance</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Gait" frame="border" id="lexi-content-abnormal-gait" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Abnormal Gait</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">122</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">123</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Patients receiving concomitant antiseizure medications</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Lack of Concentration" frame="border" id="lexi-content-lack-of-concentration" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Lack of Concentration</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Speech Disturbance" frame="border" id="lexi-content-speech-disturbance" rules="all">
<caption style="text-align:center;">
<b>Oxcarbazepine: Adverse Reaction: Speech Disturbance</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Oxcarbazepine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">139</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive therapy/monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,400 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">86</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Monotherapy in patients previously treated with other antiseizure medications</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">171</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">600 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release oral</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">163</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">166</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjunctive Therapy</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (ER, IR: 2% to 7%), back pain (4%), muscle spasm (2%), sprain (2%), tremor (ER, IR: 4% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (ER: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (2%), otic infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (3%), cough (5%), epistaxis (4%), nasopharyngitis (ER: 3%), pharyngitis (3%), pneumonia (2%), pulmonary infection (4%), rhinitis (10%), sinusitis (ER, IR: 3% to 4%), upper respiratory tract infection (7% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Suicidal ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac failure, flushing, hypertension, orthostatic hypotension, palpitations, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, contact dermatitis, eczema, erythematosus rash, facial rash, folliculitis, genital pruritus, maculopapular rash, miliaria, psoriasis, skin photosensitivity, vitiligo</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, decreased T4, heavy menstrual bleeding, hyperglycemia, hypocalcemia, hypoglycemia, hypokalemia, increased gamma-glutamyl transferase, intermenstrual bleeding, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis, biliary colic, blood in stool, cholelithiasis, colitis, duodenal ulcer, dysphagia, enteritis, eructation, esophagitis, flatulence, gastric ulcer, gingival hemorrhage, gingival hyperplasia, hematemesis, hemorrhoids, hiccups, increased appetite, retching, sialadenitis, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, hematuria, leukorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, apathy, aphasia, aura, cerebral hemorrhage, delirium, delusion, dystonia, euphoria, extrapyramidal reaction, hemiplegia, hyperreflexia, hypertonia, hyporeflexia, hypotonia, hysteria, impaired consciousness, intoxicated feeling, malaise, manic behavior, migraine, neuralgia, nightmares, panic disorder, paralysis, personality disorder, precordial pain, psychomotor retardation, psychosis, rigors, stupor, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity, hypokinesia, right hypochondrium pain, systemic lupus erythematosus, tetany</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance, blepharoptosis, cataract, conjunctival hemorrhage, hemianopia, mydriasis, ocular edema, photophobia, scotoma, xerophthalmia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis externa</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis, polyuria, renal pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, dyspnea, laryngismus, pleurisy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, Stevens-Johnson syndrome (Chung 2021), toxic epidermal necrolysis (Chung 2021), urticaria (Kim 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypothyroidism, SIADH</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum amylase, increased serum lipase, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Priapism (Negin 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, leukopenia (Jung 2019, Milia 2008), pancytopenia (Calamaras 2007, Jung 2019), thrombocytopenia (Tutor-Crespo 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Hsu 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Knudsen 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Chung 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dysarthria</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (long-term therapy) (Cheng 2019, Vestergaard 2004), decreased bone mineral density (long-term therapy), osteoporosis (long-term therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Oculogyric crisis (Gatzonis 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (Hamed 2017)</p></div>
<div class="block coi drugH1Div" id="F204769"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to oxcarbazepine, eslicarbazepine acetate, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F204751"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Clinical trials excluded patients with significant cardiovascular disease or ECG abnormalities. Monitor body weight/fluid retention in patients with HF; evaluate serum sodium with worsening cardiac function or fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Single-dose studies show that half-life of the primary active metabolite is prolonged 3- to 4-fold and AUC is doubled in patients with CrCl &lt;30 mL/minute; dose adjustment required in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Exacerbation of or new onset primary generalized seizures has been reported, particularly in children. In case of seizure aggravation, discontinue oxcarbazepine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878573"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Trileptal and Oxtellar XR are not bioequivalent and not interchangeable on a mg-per-mg basis; systemic absorption and resulting serum concentrations are lower with once-daily Oxtellar XR compared to twice-daily Trileptal when administered at the same total daily dose; higher doses of Oxtellar XR may be necessary.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F204762"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trileptal: 300 mg/5 mL (250 mL) [contains alcohol, usp, methyl hydroxybenzoate, propyl hydroxybenzoate, propylene glycol, saccharin sodium; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg/5 mL (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trileptal: 150 mg, 300 mg, 600 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg, 600 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oxtellar XR: 150 mg, 300 mg, 600 mg</p></div>
<div class="block geq drugH1Div" id="F204747"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F204771"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (OXcarbazepine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/5 mL (per mL): $1.09 - $1.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Trileptal Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg/5 mL (per mL): $2.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Oxtellar XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $10.84</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $15.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $27.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (OXcarbazepine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.68 - $1.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.01 - $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $2.01 - $4.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Trileptal Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $5.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $9.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $17.50</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867793"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trileptal: 60 mg/mL (250 mL) [contains alcohol, usp, methylparaben, polyethylene glycol (macrogol), propylene glycol, propylparaben, saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Trileptal: 300 mg, 600 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg, 600 mg</p></div>
<div class="block adm drugH1Div" id="F204766"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Administer twice daily without regard to meals.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Suspension:</i> Prior to using for the first time, firmly insert the plastic adapter provided with the bottle. Cover adapter with child-resistant cap when not in use. Shake bottle for at least 10 seconds, remove child-resistant cap, and insert the oral dosing syringe provided to withdraw appropriate dose. Dose may be taken directly from oral syringe or may be mixed in a small glass of water immediately prior to swallowing. Rinse syringe with warm water after use and allow to dry thoroughly. Discard any unused portion after 7 weeks of first opening bottle.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Administer once daily on an empty stomach at least 1 hour before or 2 hours after food. Swallow whole; do not cut, crush, or chew the tablets.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR and oral suspension formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, conversion to an IR or suspension formulation is advised for high-risk labeled and off-label indications.</p></div>
<div class="block admp drugH1Div" id="F52613492"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: May be taken without regard to meals</p>
<p style="text-indent:-2em;margin-left:6em;">Suspension: Prior to using for the first time, firmly insert the manufacturer supplied plastic adapter into the neck of the bottle; cover the adapter with child-resistant cap when not in use; shake suspension well (for at least 10 seconds) before use; use manufacturer supplied oral syringe to withdraw appropriate dose; dose may be administered directly from syringe or mixed in a small amount of water immediately prior to use; after use, rinse oral syringe with warm water and allow to dry thoroughly; discard any unused portion 7 weeks after first opening bottle</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Administer on an empty stomach at least 1 hour before or 2 hours after food. Swallow whole; do not cut, crush, or chew the tablets.</p></div>
<div class="block hazard drugH1Div" id="F49133438"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F12617171"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Trileptal: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM246799.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F%2BBtau8Jzc5BLV85NUiGV68nh45h%2B2sg410MW3pb%2FXP%2Fw%3D%3D&amp;TOPIC_ID=9467" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf</a></p>
<p style="text-indent:-2em;margin-left:4em;margin-top:0em;">Oxtellar XR: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2FUCM326087.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9BK5et6GehFK9IioulPK5Wbk3HL%2F5hJBeW0lK%2F6jL%2FZg%3D%3D&amp;TOPIC_ID=9467" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf</a></p></div>
<div class="block use drugH1Div" id="F204765"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal </b>
<b>(partial) onset seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Monotherapy or adjunctive therapy in the treatment of focal (partial) onset seizures in adults, as monotherapy in the treatment of focal (partial) onset seizures in children ≥4 years of age with epilepsy, and as adjunctive therapy in children ≥2 years of age with focal (partial) onset seizures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Treatment of focal (partial) onset seizures in adults and in children ≥6 years of age.</p></div>
<div class="block off-label drugH1Div" id="F25730958"><span class="drugH1">Use: Off-Label: Adult</span><p>Trigeminal neuralgia</p></div>
<div class="block mst drugH1Div" id="F6224110"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">OXcarbazepine may be confused with carBAMazepine, oxaprozin, oxazepam</p>
<p style="text-indent:-2em;margin-left:4em;">Trileptal may be confused with TriLipix</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Oxcarbazepine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F204818"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F204756"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of OXcarbazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: OXcarbazepine may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: OXcarbazepine may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative antiseizure drug with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: OXcarbazepine may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: OXcarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider an alternative antiseizure medication when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of OXcarbazepine. Specifically, the concentrations of the 10-monohydroxy active metabolite of oxcarbazepine may be decreased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: OXcarbazepine may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: OXcarbazepine may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: OXcarbazepine may decrease the serum concentration of Elvitegravir.  Management: For elvitegravir plus a ritonavir-boosted protease inhibitor, use of oxcarbazepine is not recommended; for elvitegravir/cobicistat/emtricitabine/tenofovir combination products, consider using an alternative antiseizure agent when possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: May enhance the adverse/toxic effect of OXcarbazepine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: OXcarbazepine may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing oxcarbazepine to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Antiseizure Agents (Sodium Channel Blockers) may enhance the arrhythmogenic effect of LamoTRIgine.  Management: Consider the risk of serious arrhythmias or death versus any expected benefit of lamotrigine in patients receiving concomitant sodium channel blockers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: OXcarbazepine may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: OXcarbazepine may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: OXcarbazepine may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May increase the serum concentration of OXcarbazepine. OXcarbazepine may decrease the serum concentration of Perampanel. Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response to perampanel and oxcarbazepine toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: OXcarbazepine may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: OXcarbazepine may decrease the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: OXcarbazepine may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: OXcarbazepine may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: OXcarbazepine may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: OXcarbazepine may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May decrease the serum concentration of OXcarbazepine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308593"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Oxcarbazepine may decrease plasma concentrations of hormonal contraceptives. Use of an additional, nonhormonal contraceptive or alternative nonhormonal birth control is recommended.</p></div>
<div class="block pri drugH1Div" id="F204772"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Oxcarbazepine, the active metabolite MHD and the inactive metabolite DHD, crosses the placenta and can be detected in the newborn (Myllynen 2001).</p>
<p style="text-indent:0em;margin-top:2em;">According to the manufacturer, limited data collected from pregnancy registries suggest congenital malformations may be associated with oxcarbazepine monotherapy, including craniofacial defects (such as oral clefts) and cardiac malformations (such as ventricular septal defects). However, use of oxcarbazepine in pregnancy is limited in comparison to other antiseizure drugs and additional information may be needed to evaluate specific birth defects and other pregnancy outcomes (de Jong 2016; Martinez Ferri 2018; Tomson 2019; Weston 2016). In general, the risk of teratogenic effects is higher with antiseizure drug polytherapy than monotherapy (Harden 2009). In case reports, symptoms similar to neonatal abstinence syndrome have been observed in newborns following in utero oxcarbazepine exposure (Chen 2017; Rolnitsky 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, plasma concentrations of the active metabolite, MHD, gradually decrease during pregnancy; patients should be monitored during pregnancy and postpartum.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to oxcarbazepine is ongoing. Patients exposed to oxcarbazepine during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F204773"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oxcarbazepine and the active 10-hydroxy metabolite (MHD) are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F204760"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Seizure frequency; serum sodium as deemed necessary (particularly during first 3 months of therapy); mental alertness and symptoms of CNS depression (dizziness, headache, somnolence); signs/symptoms of skin reactions; hypersensitivity reactions, including DRESS (eg, disparate manifestations associated with lymphatic, hepatic, renal, cardiovascular, and/or hematologic organ systems). Additional serum sodium monitoring recommended during maintenance treatment in patients receiving other medications known to decrease sodium levels, in patients with signs/symptoms of hyponatremia (eg, nausea, malaise, headache, lethargy, confusion, impaired consciousness, seizures), older adult patients, and in patients with an increase in seizure frequency or severity. Periodic thyroid function tests (particularly pediatric patients) and CBC. Monitor for suicidality (eg, suicidal thoughts, depression, behavioral changes). Serum levels of concomitant antiseizure drugs during titration as necessary.</p>
<p style="text-indent:0em;margin-top:2em;">Consider screening patients of Asian descent for the variant human leukocyte antigen (HLA) allele B*1502 prior to initiating therapy. Screening is not recommended in low-risk populations or in current oxcarbazepine patients (risk usually during first few months of therapy).</p></div>
<div class="block rer drugH1Div" id="F27122133"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">The metabolite of oxcarbazepine, 10-monohydroxy metabolite (MHD), is considered the active entity primarily responsible for the therapeutic effects. A number of studies have suggested optimal MHD concentrations for efficacy may range from 2 to 55 mcg/mL and some experts suggest a target range of 8 to 35 mcg/mL based on clinical experience; however, a clear correlation between plasma concentrations and therapeutic response has not been demonstrated. Therapeutic drug monitoring of MHD is not routinely warranted; however, it may be beneficial in optimizing seizure control in the following situations: Extremes of age, during pregnancy, to investigate the correlation between drug concentrations and toxicity especially with concurrent disease states such as renal impairment, to identify potential drug interactions, to assess reasons for therapeutic failure, or to rule out noncompliance (Bring 2008; May 2003).</p></div>
<div class="block pha drugH1Div" id="F204750"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pharmacological activity results from both oxcarbazepine and its monohydroxy metabolite (MHD). Precise mechanism of antiseizure effect has not been defined. Oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing the propagation of synaptic impulses. These actions are believed to prevent the spread of seizures. Oxcarbazepine and MHD also increase potassium conductance and modulate the activity of high-voltage activated calcium channels.</p></div>
<div class="block phk drugH1Div" id="F204768"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Complete</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: MHD: V<sub>d</sub>: 49 L</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Oxcarbazepine: 67%; MHD: 40%, primarily to albumin; parent drug and metabolite do not bind to alpha-1 acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Oxcarbazepine is extensively metabolized in the liver to its active 10-monohydroxy metabolite (MHD); MHD undergoes further metabolism via glucuronide conjugation; 4% of dose is oxidized to the 10,11-dihydroxy metabolite (DHD) (inactive); 70% of serum concentration appears as MHD, 2% as unchanged oxcarbazepine, and the rest as minor metabolites; <b>Note:</b> Unlike carbamazepine, autoinduction of metabolism has not been observed and biotransformation of oxcarbazepine does not result in an epoxide metabolite </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Immediate release tablets and suspension have similar bioavailability (based on MDH serum concentrations). Extended release tablets and immediate release products are not bioequivalent. Immediate release: Decreased in children &lt;8 years; increased in elderly &gt;60 years </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children (Rey 2004): 2 to 5 years: MHD: Single dose: Mean range: 4.8 to 6.7 hours; 6 to 12 years: MHD: Single dose: Mean range: 7.2 to 9.3 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Immediate release: Parent drug: 2 hours; MHD: 9 hours; renal impairment (CrCl 30 mL/minute): MHD: 19 hours; Extended release: Parent drug: 7 to 11 hours; MHD: 9 to 11 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 2 to 12 years: Immediate release: Oxcarbazepine: 1 hour; MHD: 3 to 4 hours (Rey 2004)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Immediate release: MHD: Tablets: Median: 4.5 hours (range: 3 to 13 hours); Suspension: Median 6 hours; Extended release: MHD: 7 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (95%, &lt;1% as unchanged oxcarbazepine, 27% as unchanged MHD, 49% as MHD glucuronides, 3% as DHD (inactive), and 13% as conjugate of oxcarbazepine and MHD); feces (&lt;4%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Clearance (per body weight): </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 2 to &lt;4 years: Increased by ∼80% compared to adults </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children 4 to 12 years: Increased by ∼40% compared to adults</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children ≥13 years: Values approach adult clearance  </p></div>
<div class="block phksp drugH1Div" id="F51160066"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: If CrCl &lt;30 mL/minute, elimination half-life of MHD is prolonged to 19 hours and there is a 2-fold increase in AUC.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Max plasma concentration and AUC values of MHD were 30% to 60% higher.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F204775"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Atoxecar | Aurene | Oxcarbazepina | Oxcarbazepina dosa | Rupox | Trileptal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepin Arcana | Trileptal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Leptal | Oxazep | Trileptal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Tevaleptin | Trileptal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Auram | Oleptal | Oxcarb | Oxcarbazepina | Trileptal | Zyoxipina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Trileptal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alox | Coxepta | Oxicodal | Trileptal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Mo yi | Ren ao | Trileptal | Wan Yi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Kallion xr | Lonazet | Nitris | Oxcar | Oxcarbazepina | Oxicodal | Oxycarbamazepina | Oxycarbazepina | Trileptal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Desidox extent | Oxcarbazepin | Oxcarbazepin 1a pharma | Oxcarbazepin CT | Oxcarbazepin Hexal | Oxcarbazepin neuraxpharm | Oxcarbazepin Ratiopharm | Oxcarbazepin Stada | Oxcarbazepin Teva | Timox | Trileptal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Actinium | Oxicodal | Trileptal | Zenoxa</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Deprectal | Oxcarbazepina | Oxcarpin | Oxetol | Oxicodal | Trileptal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Oxcarbazepine Teva | Trileptal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Andoxezine | Oxaleptal | Oxatrilepazine | Oxigrex | Shorsalin | Trileptal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Epilexter | Oxcarbazepina cinfa | Oxcarbazepina normon | Oxcarbazepina pensa | Oxcarbazepina Tecnigen | Oxcarbazepina Teva | Oxcarmylan | Trileptal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Apydan desitin | Oxcarbazepin orion | Oxcarbazepine stada | Trileptal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine Mylan | Oxcarbazepine Sandoz | Oxcarbazepine Teva | Trileptal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine Generics | Oxcarbazepine/Generics | Trileptal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Oxalept | Trileptal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Trileptal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Trexapin | Trileptin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Auxigin | Carbanerve | Carbox | Eoptal | Epigold xr | Epizox od | Epocarb | Euresta | Fobigone ox | Lovax | Mezalog | Nictal | Olepsy | Oleptal | Ox-mazetol | Oxalepsy | Oxana | Oxcarb | Oxcazo | Oxcee | Oxene | Oxep | Oxepin | Oxepin sr | Oxeptal | Oxetol | Oxicar | Oxileptin | Oxmazetol | Oxrate | Oxring | Oxyrise od | Psycarb | Seizurone OX | Selzic | Trioptal | Vinlep | Zenoxa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepina MG | Oxcarbazepina Tecnigen | Tolep | Zigabal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbatol | Trileptal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Oxazepine | Oxpin | Trileptal | Triptal | Unilepsy</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine Teva | Trileptal</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine Teva | Trileptal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Actinium | Deprectal | Deprectal S | Kallion xr | Mhide | Obepanac | Oxcarbazepina | Oxetol | Sinfonil | Trileptal | Zetoxen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine Jubilant | Oxcarbazepine Sandoz | Trileptal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apydan extent | Timox | Trileptal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Deprectal | Lakproplus | Oxetol | Oxicodal | Oxolon | Selzic | Trileptal</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Carbox | Kusapin | Oleptal | Trileptal</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Oxalepsy | Oxaze | Oxcarb | Oxicarb | Telox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apydan | Karbostad | Oxcarbazepin NeuroPharma | Oxepilax | Trileptal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxtellar xr | Trileptal</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Epilfarmo | Proaxen | Zigabal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fluxaten | Oxantakal | Oxcarbazepina dallas | Oxcarbazepina dosa | Oxcarbazepina heisecke | Oxicodal | Oxidan | Quimiun | Trileptal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepine native | Trileptal</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Carpazio | Trileptal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepin mylan | Oxcarbazepine stada | Trileptal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Karbox | Okskarbazepin Stada | Trileptal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Apilep | Epsile | Oxcarpin | Trileptal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Trileptal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Oxapin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Oxeptal | Trileptal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepina | Oxolon | Trileptal</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Oxcarbazepina | Oxicodal | Trileptal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Carbamaz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mylan oxcarbazepine | Trileptal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HazardousDrugs.2017">
<a name="HazardousDrugs.2017"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28256714">
<a name="28256714"></a>Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MSY, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. <i>Br J Dermatol</i>. 2017;177(5):1234-1247. doi:10.1111/bjd.15423<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/28256714/pubmed" id="28256714" target="_blank">28256714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25369238">
<a name="25369238"></a>Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome. <i>Br J Dermatol</i>. 2015;172(4):1090-1095. doi:10.1111/bjd.13512<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/25369238/pubmed" id="25369238" target="_blank">25369238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18490142">
<a name="18490142"></a>Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. <i>Epilepsy Res</i>. 2008;80(2-3):194-200. doi:10.1016/j.eplepsyres.2008.04.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18490142/pubmed" id="18490142" target="_blank">18490142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818889">
<a name="20818889"></a>Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. <i>N Engl J Med</i>. 2010;363(6):542-551. doi:10.1056/NEJMoa0909801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20818889/pubmed" id="20818889" target="_blank">20818889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18505998">
<a name="18505998"></a>Azar NJ, Wright AT, Wang L, Song Y, Abou-Khalil BW. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal. <i>Neurology</i>. 2008;70(22, pt 2):2187-2188. doi:10.1212/01.wnl.0000313152.89906.5a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18505998/pubmed" id="18505998" target="_blank">18505998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453718">
<a name="19453718"></a>Bell GS, Gaitatzis A, Bell CL, Johnson AL, Sander JW. Suicide in people with epilepsy: how great is the risk? <i>Epilepsia</i>. 2009;50(8):1933-1942. doi:10.1111/j.1528-1167.2009.02106.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19453718/pubmed" id="19453718" target="_blank">19453718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28190254">
<a name="28190254"></a>Bellivier F, Belzeaux R, Scott J, Courtet P, Golmard JL, Azorin JM. Anticonvulsants and suicide attempts in bipolar I disorders. <i>Acta Psychiatr Scand</i>. 2017;135(5):470-478. doi:10.1111/acps.12709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/28190254/pubmed" id="28190254" target="_blank">28190254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30860637">
<a name="30860637"></a>Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. <i>Eur J Neurol</i>. 2019;26(6):831-849. doi:10.1111/ene.13950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/30860637/pubmed" id="30860637" target="_blank">30860637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28542738">
<a name="28542738"></a>Berghuis B, van der Palen J, de Haan GJ, Lindhout D, Koeleman BPC, Sander JW; EpiPGX Consortium. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. <i>Epilepsia</i>. 2017;58(7):1227-1233. doi:10.1111/epi.13777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/28542738/pubmed" id="28542738" target="_blank">28542738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11444724">
<a name="11444724"></a>Besag FM. Behavioural effects of the new anticonvulsants. <i>Drug Saf</i>. 2001;24(7):513-536. doi:10.2165/00002018-200124070-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/11444724/pubmed" id="11444724" target="_blank">11444724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881247">
<a name="10881247"></a>Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. <i>Neurology</i>. 2000;54(12):2245-2251. doi:10.1212/wnl.54.12.2245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/10881247/pubmed" id="10881247" target="_blank">10881247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25933949">
<a name="25933949"></a>Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: An update. <i>Pharmacol Rep</i>. 2015;67(3):426-434. doi:10.1016/j.pharep.2014.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/25933949/pubmed" id="25933949" target="_blank">25933949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23744424">
<a name="23744424"></a>Błaszczyk B, Szpringer M, Czuczwar SJ, Lasoń W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. <i>Pharmacol Rep</i>. 2013;65(2):399-409. doi:10.1016/s1734-1140(13)71015-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23744424/pubmed" id="23744424" target="_blank">23744424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19026033">
<a name="19026033"></a>Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. <i>Clin Pharmacokinet</i>. 2008;47(12):767-778. doi: 10.2165/0003088-200847120-00002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19026033/pubmed" id="19026033" target="_blank">19026033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701630">
<a name="21701630"></a>Britton JW, Shih JJ. Antiepileptic drugs and suicidality. <i>Drug Healthc Patient Saf</i>. 2010;2:181-189. doi:10.2147/DHPS.S13225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/21701630/pubmed" id="21701630" target="_blank">21701630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20132298">
<a name="20132298"></a>Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. <i>Epilepsia</i>. 2010;51(5):818-829. doi:10.1111/j.1528-1167.2009.02489.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20132298/pubmed" id="20132298" target="_blank">20132298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414253">
<a name="17414253"></a>Calamaras MR, Stowe ZN, Newport DJ. Pancytopenia associated with the introduction of oxcarbazepine. <i>J Clin Psychopharmacol</i>. 2007;27(2):217-218. doi:10.1097/01.jcp.0000264971.92828.b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/17414253/pubmed" id="17414253" target="_blank">17414253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27913699">
<a name="27913699"></a>Chen CB, Hsiao YH, Wu T, et al; Taiwan Severe Cutaneous Adverse Reaction Consortium. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. <i>Neurology</i>. 2017;88(1):78-86. doi:10.1212/WNL.0000000000003453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27913699/pubmed" id="27913699" target="_blank">27913699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28543284">
<a name="28543284"></a>Chen CY, Li X, Ma LY, et al. In utero oxcarbazepine exposure and neonatal abstinence syndrome: case report and brief review of the literature. <i>Pharmacotherapy</i>. 2017;37(7):e71-e75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/28543284/pubmed" id="28543284" target="_blank">28543284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30362853">
<a name="30362853"></a>Cheng HH, Huang WC, Jeng SY. Anti-epileptic drugs associated with fractures in the elderly: a preliminary population-based study. <i>Curr Med Res Opin</i>. 2019;35(5):903-907. doi:10.1080/03007995.2018.1541447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/30362853/pubmed" id="30362853" target="_blank">30362853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33188522">
<a name="33188522"></a>Chung SJ, Ahn KM, Oh JH, Shim JS, Park HW. Incidence rates of severe cutaneous adverse reactions due to antiseizure medication: A nationwide study using health claims data in Korea. <i>Epilepsia</i>. 2021;62(1):250-257. doi:10.1111/epi.16751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/33188522/pubmed" id="33188522" target="_blank">33188522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27398292">
<a name="27398292"></a>de Jong J, Garne E, de Jong-van den Berg LT, Wang H. The risk of specific congenital anomalies in relation to newer antiepileptic drugs: a literature review. <i>Drugs Real World Outcomes</i>. 2016;3(2):131-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27398292/pubmed" id="27398292" target="_blank">27398292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16139183">
<a name="16139183"></a>Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. <i>Eur J Pain</i>. 2005;9(5):543–554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16139183/pubmed" id="16139183" target="_blank">16139183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16380624">
<a name="16380624"></a>Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. <i>Neurology</i>. 2005;65(12):1976-1978. doi:10.1212/01.wnl.0000188819.45330.90<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16380624/pubmed" id="16380624" target="_blank">16380624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18821094">
<a name="18821094"></a>D'Orazio JL. Oxcarbazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Clin Toxicol (Phila)</i>. 2008;46(10):1093-1094. doi:10.1080/15563650802342104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18821094/pubmed" id="18821094" target="_blank">18821094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2240224">
<a name="2240224"></a>Ferraris RP, Yasharpour S, Lloyd KC, Mirzayan R, Diamond JM. Luminal glucose concentrations in the gut under normal conditions. <i>Am J Physiol</i>. 1990;259(5 Pt 1):G822-G837. doi: 10.1152/ajpgi.1990.259.5.G822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/2240224/pubmed" id="2240224" target="_blank">2240224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24359313">
<a name="24359313"></a>French JA, Baroldi P, Brittain ST, Johnson JK; PROSPER Investigators Study Group. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. <i>Acta Neurol Scand</i>. 2014;129(3):143-153. doi:10.1111/ane.12207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/24359313/pubmed" id="24359313" target="_blank">24359313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19949566">
<a name="19949566"></a>Garnett WR, St Louis EK, Henry TR, Bramley T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. <i>Curr Neuropharmacol</i>. 2009;7(2):83-95. doi:10.2174/157015909788848884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19949566/pubmed" id="19949566" target="_blank">19949566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10371552">
<a name="10371552"></a>Gatzonis SD, Georgaculias N, Singounas E, Jenkins A, Stamboulis E, Siafakas A. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. <i>Neurology</i>. 1999;52(9):1918-1919. doi:10.1212/wnl.52.9.1918<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/10371552/pubmed" id="10371552" target="_blank">10371552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10881246">
<a name="10881246"></a>Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. <i>Neurology</i>. 2000;54(12):2237-2244. doi:10.1212/wnl.54.12.2237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/10881246/pubmed" id="10881246" target="_blank">10881246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378142">
<a name="18378142"></a>Gomez-Arguelles JM, Dorado R, Sepulveda JM, et al. Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgia. <i>J Clin Neurosci</i>. 2008;15(5):516-519. doi:10.1016/j.jocn.2007.04.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18378142/pubmed" id="18378142" target="_blank">18378142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26288485">
<a name="26288485"></a>Guleria VS, Sharda C, Rana T, Sood AK. Oxcarbazepine induced toxic epidermal necrolysis - a rare case report.<i> Indian J Pharmacol</i>. 2015;47(4):459-461. doi:10.4103/0253-7613.161279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/26288485/pubmed" id="26288485" target="_blank">26288485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28838247">
<a name="28838247"></a>Hamed SA. The auditory and vestibular toxicities induced by antiepileptic drugs. <i>Expert Opin Drug Saf</i>. 2017;16(11):1281-1294. doi:10.1080/14740338.2017.1372420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/28838247/pubmed" id="28838247" target="_blank">28838247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology.</i> 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21157540">
<a name="21157540"></a>Hesdorffer DC, Berg AT, Kanner AM. An update on antiepileptic drugs and suicide: are there definitive answers yet? <i>Epilepsy Curr</i>. 2010;10(6):137-145. doi:10.1111/j.1535-7511.2010.01382.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/21157540/pubmed" id="21157540" target="_blank">21157540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496806">
<a name="19496806"></a>Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? <i>Epilepsia</i>. 2009;50(5):978-986. doi:10.1111/j.1528-1167.2009.02012.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19496806/pubmed" id="19496806" target="_blank">19496806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18981374">
<a name="18981374"></a>Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW. Cross-sensitivity of skin rashes with antiepileptic drug use. <i>Neurology</i>. 2008;71(19):1527-1534. doi:10.1212/01.wnl.0000334295.50403.4c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18981374/pubmed" id="18981374" target="_blank">18981374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.1">
<a name="Ho.1"></a>Ho CC, Khan SA, Whealy MA. Trigeminal neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed March 12, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12571784">
<a name="12571784"></a>Holtmann M, Krause M, Opp J, Tokarzewski M, Korn-Merker E, Boenigk HE. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. <i>Neuropediatrics</i>. 2002;33(6):298-300. doi:10.1055/s-2002-37081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/12571784/pubmed" id="12571784" target="_blank">12571784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20958883">
<a name="20958883"></a>Hsu HF, Huang SY. Severe hepatitis associated with administration of oxcarbazepine. <i>Pediatr Int.</i> 2010;52(4):677-678. doi: 10.1111/j.1442-200X.2010.03154.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20958883/pubmed" id="20958883" target="_blank">20958883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30999724">
<a name="30999724"></a>Jung GH, You SJ. Evaluation of hematologic profile may be needed for patients treated with oxcarbazepine. <i>Korean J Pediatr</i>. 2019;62(8):312-316. doi:10.3345/kjp.2019.00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/30999724/pubmed" id="30999724" target="_blank">30999724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18698874">
<a name="18698874"></a>Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. <i>CNS Drugs</i>. 2008;22(9):739-760. doi:10.2165/00023210-200822090-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18698874/pubmed" id="18698874" target="_blank">18698874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30605267">
<a name="30605267"></a>Khalid K, Kwak BS, Leo RJ. Oxcarbazepine-induced Stevens-Johnson syndrome. <i>Prim Care Companion CNS Disord</i>. 2018;20(6):18l02304. doi:10.4088/PCC.18l02304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/30605267/pubmed" id="30605267" target="_blank">30605267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610167">
<a name="29610167"></a>Kim H, Chadwick L, Alzaidi Y, Picker J, Poduri A, Manzi S. <i>HLA-A*31:01</i> and oxcarbazepine-induced DRESS in a patient with seizures and complete <i>DCX</i> deletion. <i>Pediatrics</i>. 2018;141(suppl 5):S434-S438. doi:10.1542/peds.2017-1361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/29610167/pubmed" id="29610167" target="_blank">29610167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31997613">
<a name="31997613"></a>Kim HK, Kim DY, Bae EK, Kim DW. Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008-2017. <i>J Korean Med Sci</i>. 2020;35(4):e17. doi:10.3346/jkms.2020.35.e17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/31997613/pubmed" id="31997613" target="_blank">31997613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24378204">
<a name="24378204"></a>Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. <i>Seizure</i>. 2014;23(3):208-212. doi:10.1016/j.seizure.2013.11.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/24378204/pubmed" id="24378204" target="_blank">24378204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31840232">
<a name="31840232"></a>Kluger N, Descamps V, Lappalainen K, Roivainen R. Facial paralysis associated with drug reaction with eosinophilia and systemic symptoms (DRESS) with oxcarbazepine and reactivation of human herpesvirus 6 (HHV-6). <i>Int J Dermatol</i>. 2020;59(4):e114-e115. doi:10.1111/ijd.14755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/31840232/pubmed" id="31840232" target="_blank">31840232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17675030">
<a name="17675030"></a>Knudsen JF, Flowers CM, Kortepeter C, Awaad Y. Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review. <i>Pediatr Neurol</i>. 2007;37(2):134-137. doi:10.1016/j.pediatrneurol.2007.03.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/17675030/pubmed" id="17675030" target="_blank">17675030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16939855">
<a name="16939855"></a>Kothare SV, Mostofi N, Khurana DS, et al. Oxcarbazepine therapy in very young children: a single-center clinical experience. <i>Pediatr Neurol</i>. 2006;35(3):173-176. doi:10.1016/j.pediatrneurol.2006.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16939855/pubmed" id="16939855" target="_blank">16939855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27730770">
<a name="27730770"></a>Lee J, Park EG, Lee M, Lee J. Desensitization to oxcarbazepine: Long-term efficacy and tolerability. <i>J Clin Neurol</i>. 2017;13(1):47-54. doi:10.3988/jcn.2017.13.1.47<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27730770/pubmed" id="27730770" target="_blank">27730770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20881597">
<a name="20881597"></a>Lin CH, Lu CH, Wang FJ, et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. <i>Clin Neuropharmacol</i>. 2010;33(6):293-296. doi:10.1097/WNF.0b013e3181f80bd4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20881597/pubmed" id="20881597" target="_blank">20881597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16962380">
<a name="16962380"></a>Martinez W, Ingenito A, Blakeslee M, Barkley GL, McCague K, D'Souza J. Efficacy, safety, and tolerability of oxcarbazepine monotherapy. <i>Epilepsy Behav</i>. 2006;9(3):448-456. doi:10.1016/j.yebeh.2006.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16962380/pubmed" id="16962380" target="_blank">16962380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27452623">
<a name="27452623"></a>Martinez Ferri M, Peña Mayor P, Perez López-Fraile I, et al. Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. <i>Neurologia</i>. 2018;33(2):78-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27452623/pubmed" id="27452623" target="_blank">27452623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12959634">
<a name="12959634"></a>May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. <i>Clin Pharmacokinet</i>. 2003;42(12):1023-1042.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/12959634/pubmed" id="12959634" target="_blank">12959634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8148215">
<a name="8148215"></a>McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. <i>Br J Clin Pharmacol</i>. 1994;37(1):27-32. doi:10.1111/j.1365-2125.1994.tb04234.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/8148215/pubmed" id="8148215" target="_blank">8148215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196947">
<a name="19196947"></a>Milia A, Pilia G, Mascia MG, Moller J, Cocco E, Marrosu MG. Oxcarbazepine-induced leukopenia. <i>J Neuropsychiatry Clin Neurosci</i>. 2008;20(4):502-503. doi:10.1176/jnp.2008.20.4.502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19196947/pubmed" id="19196947" target="_blank">19196947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27086495">
<a name="27086495"></a>Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson Syndrome and toxic epidermal necrolysis: An analysis of triggers and implications for improving prevention. <i>Am J Med</i>. 2016;129(11):1221-1225. doi:10.1016/j.amjmed.2016.03.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27086495/pubmed" id="27086495" target="_blank">27086495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22994856">
<a name="22994856"></a>Mula M, Kanner AM, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: an expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. <i>Epilepsia</i>. 2013;54(1):199-203. doi:10.1111/j.1528-1167.2012.03688.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/22994856/pubmed" id="22994856" target="_blank">22994856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11879354">
<a name="11879354"></a>Myllynen P, Pienimäki P, Jouppila P, Vähäkangas K. Transplacental passage of oxcarbazepine and its metabolites in vivo. <i>Epilepsia</i>. 2001;42(11):1482-1485. doi:10.1046/j.1528-1157.2001.14301.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/11879354/pubmed" id="11879354" target="_blank">11879354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: Diagnosis and management. Clinical guideline (CG183). September 3, 2014. https://www.nice.org.uk/guidance/cg183.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2020">
<a name="NICE.2020"></a>National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. Clinical guideline [CG137]. Updated February 11, 2020. http://www.nice.org.uk/guidance/cg137.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16292111">
<a name="16292111"></a>Negin B, Murphy TK. Priapism associated with oxcarbazepine, aripiprazole, and lithium. <i>J Am Acad Child Adolesc Psychiatry</i>. 2005;44(12):1223-1224. doi:10.1097/01.chi.0000183496.44266.bd<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16292111/pubmed" id="16292111" target="_blank">16292111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243221">
<a name="16243221"></a>Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. <i>Pediatr Neurol</i>. 2005;33(5):337-344. doi:10.1016/j.pediatrneurol.2005.05.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16243221/pubmed" id="16243221" target="_blank">16243221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oxtellar.2018.12">
<a name="Oxtellar.2018.12"></a>Oxtellar XR (oxcarbazepine) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20388896">
<a name="20388896"></a>Patorno E, Bohn RL, Wahl PM, etal. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. <i>JAMA</i>. 2010;303(14):1401-1419. doi:10.1001/jama.2010.410. Erratum in: <i>JAMA</i>. 2010;303(22):2252. Dosage error in article text.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/20388896/pubmed" id="20388896" target="_blank">20388896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23375513">
<a name="23375513"></a>Pereira A, Gitlin MJ, Gross RA, Posner K, Dworkin RH. Suicidality associated with antiepileptic drugs: implications for the treatment of neuropathic pain and fibromyalgia. <i>Pain</i>. 2013;154(3):345-349. doi:10.1016/j.pain.2012.12.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23375513/pubmed" id="23375513" target="_blank">23375513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29392710">
<a name="29392710"></a>Phillips EJ, Sukasem C, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. <i>Clin Pharmacol Ther</i>. 2018;103(4):574-581. doi:10.1002/cpt.1004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/29392710/pubmed" id="29392710" target="_blank">29392710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16275822">
<a name="16275822"></a>Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. <i>Neurology</i>. 2005;65(9):1370-1375. doi:10.1212/01.wnl.0000186800.18456.72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/16275822/pubmed" id="16275822" target="_blank">16275822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15496647">
<a name="15496647"></a>Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. <i>J Clin Pharmacol</i>. 2004;44(11):1290-1300. doi:10.1177/0091270004266617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/15496647/pubmed" id="15496647" target="_blank">15496647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23668873">
<a name="23668873"></a>Rolnitsky A, Merlob P, Klinger G. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. <i>Pediatr Neurol</i>. 2013;48(6):466-468.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23668873/pubmed" id="23668873" target="_blank">23668873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12112108">
<a name="12112108"></a>Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. <i>Ann Neurol</i>. 2002;51(5):613-620. doi:10.1002/ana.10190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/12112108/pubmed" id="12112108" target="_blank">12112108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.1">
<a name="Schachter.1"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed December 8, 2020a. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.2">
<a name="Schachter.2"></a>Schachter SC. Overview of the management of epilepsy in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed December 9, 2020b. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26339470">
<a name="26339470"></a>Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. <i>Clin Transl Allergy</i>. 2015;5:31. doi:10.1186/s13601-015-0073-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/26339470/pubmed" id="26339470" target="_blank">26339470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23997949">
<a name="23997949"></a>Shvarts V, Chung S. Epilepsy, antiseizure therapy, and sleep cycle parameters. <i>Epilepsy Res Treat</i>. 2013;2013:670682. doi:10.1155/2013/670682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23997949/pubmed" id="23997949" target="_blank">23997949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29370880">
<a name="29370880"></a>Tangamornsuksan W, Scholfield N, Lohitnavy M. Association between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions: A systematic review and meta-analysis. <i>J Pharm Pharm Sci</i>. 2018;21(1):1-18. doi:10.18433/J36S7D<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/29370880/pubmed" id="29370880" target="_blank">29370880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664067">
<a name="30664067"></a>Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. <i>Curr Opin Neurol</i>. 2019;32(2):246-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/30664067/pubmed" id="30664067" target="_blank">30664067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trileptal.1">
<a name="Trileptal.1"></a>Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trileptal.2">
<a name="Trileptal.2"></a>Trileptal (oxcarbazepine) [prescribing information]. East Hanover, NJ: Novartis; March 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17690747">
<a name="17690747"></a>Tutor-Crespo MJ, Hermida J, Tutor JC. Relation of blood platelet count during carbamazepine and oxcarbazepine treatment with daily dose, and serum concentrations of carbamazepine, carbamazepine-10, 11-epoxide, and 10-hydroxycarbazepine. <i>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</i>. 2007;151(1):91-94. doi:10.5507/bp.2007.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/17690747/pubmed" id="17690747" target="_blank">17690747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8112243">
<a name="8112243"></a>Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. <i>Epilepsia</i>. 1994;35(1):181-188. doi:10.1111/j.1528-1157.1994.tb02930.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/8112243/pubmed" id="8112243" target="_blank">8112243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22161387">
<a name="22161387"></a>Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute effective episodes in bipolar disorder. <i>Cochrane Database Syst Rev</i>. 2011;(12):CD004857.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/22161387/pubmed" id="22161387" target="_blank">22161387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18254071">
<a name="18254071"></a>Vasudev A, Macritchie K, Watson S, Geddes J, Young AH. Oxcarbazepine in the maintenance treatment of bipolar disorder. <i>Cochrane Database Syst Rev</i>. 2008;(1):CD005171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/18254071/pubmed" id="18254071" target="_blank">18254071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15509233">
<a name="15509233"></a>Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. <i>Epilepsia</i>. 2004;45(11):1330-1337. doi:10.1111/j.0013-9580.2004.18804.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/15509233/pubmed" id="15509233" target="_blank">15509233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24081427">
<a name="24081427"></a>Wei SH, Liu CC, Fan PC. A comparison of the efficacy and tolerability of oxcarbazepine oral suspension between infants and children with epilepsy: a retrospective chart review at a single medical center in Taiwan. <i>Paediatr Drugs</i>. 2014;16(1):83-89. doi:10.1007/s40272-013-0049-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/24081427/pubmed" id="24081427" target="_blank">24081427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11460891">
<a name="11460891"></a>Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. <i>CNS Drugs</i>. 2001;15(2):137-163. doi:10.2165/00023210-200115020-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/11460891/pubmed" id="11460891" target="_blank">11460891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27819746">
<a name="27819746"></a>Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. <i>Cochrane Database Syst Rev</i>. 2016;11:CD010224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/27819746/pubmed" id="27819746" target="_blank">27819746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23543558">
<a name="23543558"></a>Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. <i>Cochrane Database Syst Rev</i>. 2013;3:CD007963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxcarbazepine-drug-information/abstract-text/23543558/pubmed" id="23543558" target="_blank">23543558</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9467 Version 495.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
